EPA:GBT - Euronext Paris - Matif - FR0000032526 - Common Stock - Currency: EUR
EPA:GBT (3/7/2025, 7:00:00 PM)
27
+0.7 (+2.66%)
The current stock price of GBT.PA is 27 EUR. In the past month the price increased by 3.85%. In the past year, price decreased by -16.92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EL.PA | ESSILORLUXOTTICA | 53.13 | 124.44B | ||
ESL.DE | ESSILORLUXOTTICA | 53.09 | 124.35B | ||
1EL.MI | ESSILORLUXOTTICA | 52.97 | 124.08B | ||
CBHD.DE | COLOPLAST-B | 33.98 | 21.00B | ||
GENT.OL | GENTIAN DIAGNOSTICS ASA | 16.31 | 721.66M | ||
ALCJ.PA | CROSSJECT | N/A | 91.07M | ||
PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 89.03M | ||
AFME.PA | AFFLUENT MEDICAL SA | N/A | 55.09M | ||
SVS.MI | SVAS BIOSANA SPA | 7.25 | 41.44M | ||
IVN.MI | IVISION TECH SPA | N/A | 16.85M |
Guerbet SA engages in the research, development, manufacture, and sale of contrast products for medical imaging. The company is headquartered in Villepinte, Ile-De-France and currently employs 2,920 full-time employees. The company produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The firm operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
GUERBET
15 rue des Vanesses, Zone Paris Nord II
Villepinte ILE-DE-FRANCE FR
Employees: 2920
Company Website: https://www.guerbet.com/
Investor Relations: http://www.guerbet.com/en/investors.html
Phone: 33145915000
The current stock price of GBT.PA is 27 EUR. The price increased by 2.66% in the last trading session.
The exchange symbol of GUERBET is GBT and it is listed on the Euronext Paris - Matif exchange.
GBT.PA stock is listed on the Euronext Paris - Matif exchange.
8 analysts have analysed GBT.PA and the average price target is 42.59 EUR. This implies a price increase of 57.72% is expected in the next year compared to the current price of 27. Check the GUERBET stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GUERBET (GBT.PA) has a market capitalization of 341.28M EUR. This makes GBT.PA a Small Cap stock.
GUERBET (GBT.PA) currently has 2920 employees.
GUERBET (GBT.PA) has a support level at 26.9 and a resistance level at 27.03. Check the full technical report for a detailed analysis of GBT.PA support and resistance levels.
The Revenue of GUERBET (GBT.PA) is expected to grow by 6.69% in the next year. Check the estimates tab for more information on the GBT.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GUERBET (GBT.PA) has a dividend yield of 1.9%. The yearly dividend amount is currently 0.5. Check the full fundamental report for a detailed analysis of GBT.PA dividend history, reliability and sustainability.
GUERBET (GBT.PA) will report earnings on 2025-03-26, after the market close.
The PE ratio for GUERBET (GBT.PA) is 10.23. This is based on the reported non-GAAP earnings per share of 2.64 and the current share price of 27 EUR. Check the full fundamental report for a full analysis of the valuation metrics for GBT.PA.
ChartMill assigns a technical rating of 2 / 10 to GBT.PA. When comparing the yearly performance of all stocks, GBT.PA is a bad performer in the overall market: 80.99% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to GBT.PA. GBT.PA has only an average score on both its financial health and profitability.
Over the last trailing twelve months GBT.PA reported a non-GAAP Earnings per Share(EPS) of 2.64. The EPS increased by 177.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.97% | ||
ROA | 3.14% | ||
ROE | 8.43% | ||
Debt/Equity | 0.97 |
ChartMill assigns a Buy % Consensus number of 85% to GBT.PA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 119.14% and a revenue growth 6.69% for GBT.PA